The inconsistent clinical efficacy of single-cytokine inhibitors (e.g. anti–IL-5 or anti–IL-17 alone) in COPD likely owes to this network effect [117], where multiple inflammatory loops compensate or parallel one another, blunting the impact of pathway-specific inhibition. Here, IL5 is linked to chronic obstructive pulmonary disease.